News
Vaxart says it can resume next-gen Covid work, will screen participants for oral vaccine trial
Vaxart said a stop-work order has been lifted on its next-generation Covid-19 vaccine efforts planned under a Biden-era ...
A bipartisan piece of legislation proposed this week would prohibit pharma companies from receiving tax deductions for direct ...
WuXi AppTec’s revenue rose for the first few months of 2025, signaling that pressures from the proposed Biosecure Act may be ...
As it awaits an FDA approval decision on apitegromab for spinal muscular atrophy, Scholar Rock is reshaping its leadership ...
Biohaven's $600M financing deal, Protara's cell therapy data, Pfizer's bladder cancer success, plus news from CG Oncology, ...
Daiichi Sankyo reaffirms US manufacturing expansion, including for Enhertu, will help with Trump's proposed tariffs. $350M ...
France’s national public health agency is suspending immunization of adults 65 years and older with Valneva’s chikungunya ...
Globally, approximately 300 million people are grappling with obesity, a complex disease that has a profound impact on a ...
Merck's Keytruda shows 27% reduced risk of recurrence/death in head & neck cancer when used before & after surgery, with FDA ...
Endpoints Weekly covers Q1 earnings from major pharma companies, with focus on tariff concerns. FDA's Makary discusses new rare disease pathway, and HuidaGene reports first brain CRISPR treatment.
Akeso Biopharma won first-line approval in China for its lung cancer drug ivonescimab, a new immunotherapy that it believes will top Merck’s megablockbuster PD-1 drug … ...
In an interview with PBS' 'NewsHour' co-anchor and co-managing editor Amna Nawaz on Thursday, Marty Makary expanded on his ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback